CVS Health Stock News

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness.

A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it overcharged Medicare for prescription drugs.

CVS Health Corp (NYSE:CVS) has been upgraded by UBS analysts who cited greater confidence in the company's recovery trajectory and multiple levers for earnings growth. The analysts upped their rating to ‘Buy' from ‘Neutral' and raised their price objective to $79 from $67, implying upside from its share price on Monday afternoon of about $70.

CVS Health is not entitled to coverage from insurers, including AIG and Chubb , against thousands of lawsuits over its role in the nation's opioid crisis, Delaware's highest court ruled on Monday.

CVS has emerged as an outlier during the ongoing implosion observed in the healthcare insurance sector, as they drive improved YoY margins despite the rising medical costs. This is on top of the somewhat stable performance metrics observed in the PBM and pharmacy end markets, as the management confidently raises the FY2025 adj EPS guidance. These directly contrast the massive pessimism observed...

Super investors like Buffett and Michael Bury piled heavily into UnitedHealthcare in Q2, signalling confidence that the sector's business model remains intact despite recent headwinds. CVS has emerged as a top performer in 2025, with strong revenue growth and raised guidance, outpacing struggling peers like UnitedHealth. The sector faces ongoing uncertainties—rising costs, regulatory scrutiny, ...

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In CVS (CVS) To Contact Him Directly To Discuss Their Options

July saw strong market gains, especially in tech, but finding bargains is tough as indices approach all-time highs. I focused July investments on high-yield BDCs like OBDC, MFIC, and BXSL, maintaining a 7.9% yield on cost. Dividend income hit a July record, up 22% year-over-year, with BDCs set to play an even bigger role in the coming months.